Leipzig Scientists Find AP503 Strengthens Bones in Mice by Activating GPR133, Targeting 6 Million Germans With Osteoporosis
Updated
Updated · ScienceDaily · Sep 9
Leipzig Scientists Find AP503 Strengthens Bones in Mice by Activating GPR133, Targeting 6 Million Germans With Osteoporosis
1 articles · Updated · ScienceDaily · Sep 9
Summary
AP503 significantly increased bone strength in both healthy and osteoporosis-model mice, giving Leipzig University researchers a new experimental route toward longer-term osteoporosis treatment.
GPR133 appears to act as a bone-building switch: activating the receptor boosted osteoblast activity while suppressing osteoclasts, shifting bone turnover toward formation rather than loss.
Genetic impairment of GPR133 caused early bone-density loss in mice, strengthening the case that the receptor is central to maintaining healthy bone.
AP503 has also been linked in earlier Leipzig research to stronger skeletal muscle, raising the prospect of a therapy that could address both bone fragility and muscle decline in aging patients.
About 6 million people in Germany have osteoporosis—mostly women—and the team is now studying whether AP503 and GPR133 could be applied beyond bone disease.